155 related articles for article (PubMed ID: 8571992)
21. MUC3 and MCA serum levels and steroid receptor content in breast cancer.
Quaranta M; Coviello M; Daniele A; Abbate I; Durrant LG; Paradiso A; Schittulli F
Int J Biol Markers; 2004; 19(2):109-14. PubMed ID: 15255542
[TBL] [Abstract][Full Text] [Related]
22. The differential diagnostic potential of a panel of tumor markers (CA 125, CA 15-3, and CA 72-4 antigens) in patients with a pelvic mass.
Schutter EM; Davelaar EM; van Kamp GJ; Verstraeten RA; Kenemans P; Verheijen RH
Am J Obstet Gynecol; 2002 Aug; 187(2):385-92. PubMed ID: 12193930
[TBL] [Abstract][Full Text] [Related]
23. Serum carcinoembryonic antigen, cancer antigen 125, cancer antigen 15-3, squamous cell carcinoma, and tumor-associated trypsin inhibitor concentrations during healthy pregnancy.
Schlageter MH; Larghero J; Cassinat B; Toubert ME; Borschneck C; Rain JD
Clin Chem; 1998 Sep; 44(9):1995-8. PubMed ID: 9732993
[No Abstract] [Full Text] [Related]
24. CA 72-4 serum marker--a new tool in the management of carcinoma patients.
Guadagni F; Roselli M; Cosimelli M; Ferroni P; Spila A; Cavaliere F; Casaldi V; Wappner G; Abbolito MR; Greiner JW
Cancer Invest; 1995; 13(2):227-38. PubMed ID: 7874576
[TBL] [Abstract][Full Text] [Related]
25. Tumour-associated antigens in maternal and fetal blood.
Hohlfeld P; Dang TT; Nahoul K; Daffos F; Forestier F
Prenat Diagn; 1994 Oct; 14(10):907-12. PubMed ID: 7899266
[TBL] [Abstract][Full Text] [Related]
26. A combination of serum tumor markers identifies high-risk patients with early-stage squamous cervical cancer.
Davelaar EM; van de Lande J; von Mensdorff-Pouilly S; Blankenstein MA; Verheijen RH; Kenemans P
Tumour Biol; 2008; 29(1):9-17. PubMed ID: 18497544
[TBL] [Abstract][Full Text] [Related]
27. Tissue polypeptide specific antigen and cancer associated serum antigen in the follow-up of ovarian cancer.
Sliutz G; Tempfer C; Kainz C; Mustafa G; Gitsch G; Koelbl H; Biegelmayer C
Anticancer Res; 1995; 15(3):1127-9. PubMed ID: 7645936
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of colorectal cancer-associated mucin CA M43 assay in serum.
van Kamp GJ; von Mensdorff-Pouilly S; Kenemans P; Verstraeten R; Yedema CA; Wobbes T; Bon GG; Kok A; Brown JP; Hilgers J
Clin Chem; 1993 Jun; 39(6):1029-32. PubMed ID: 8504532
[TBL] [Abstract][Full Text] [Related]
29. Studies on angiogenesis in the benign and malignant ovarian neoplasms with the use of color and pulsed Doppler sonography and serum CA-125, CA-19.9, CA-72.4 and vascular endothelial growth factor measurements.
Czekierdowski A
Ann Univ Mariae Curie Sklodowska Med; 2002; 57(1):113-31. PubMed ID: 12898913
[TBL] [Abstract][Full Text] [Related]
30. Serum sialyl Tn as an independent predictor of poor prognosis in patients with epithelial ovarian cancer.
Kobayashi H; Terao T; Kawashima Y
J Clin Oncol; 1992 Jan; 10(1):95-101. PubMed ID: 1727929
[TBL] [Abstract][Full Text] [Related]
31. Discordant serum CA 125 values in commercial immunoassays.
van Kamp GJ; Verstraeten AA; Kenemans P
Eur J Obstet Gynecol Reprod Biol; 1993 Apr; 49(1-2):99-103. PubMed ID: 8365530
[TBL] [Abstract][Full Text] [Related]
32. The use of mucin-specific monoclonal antibodies and lectins in the detection of tumor-associated serum markers in gynecological cancer.
Devine PL; McGuckin MA; Ramm LE; Harada H; Ward BG
Cancer Biochem Biophys; 1993 Sep; 13(4):221-38. PubMed ID: 8521372
[TBL] [Abstract][Full Text] [Related]
33. Use of tetranectin, CA-125 and CASA to predict residual tumor and survival at second- and third-look operations for ovarian cancer.
Høgdall CK; Høgdall EV; Hørding U; Toftager-Larsen K; Arends J; Nørgaard-Pedersen B; Clemmensen I
Acta Oncol; 1996; 35(1):63-9. PubMed ID: 8619942
[TBL] [Abstract][Full Text] [Related]
34. Clinical evaluation of circulating serum sialyl Tn antigen levels in patients with epithelial ovarian cancer.
Kobayashi H; Terao T; Kawashima Y
J Clin Oncol; 1991 Jun; 9(6):983-7. PubMed ID: 1851822
[TBL] [Abstract][Full Text] [Related]
35. Predictive and prognostic values of cancer-associated serum antigen (CASA) and cancer antigen 125 (CA 125) levels prior to second-look laparotomy for ovarian cancer.
Kierkegaard O; Mogensen O; Mogensen B; Jakobsen A
Gynecol Oncol; 1995 Nov; 59(2):251-4. PubMed ID: 7590482
[TBL] [Abstract][Full Text] [Related]
36. Clinical significance of combined detection of serum tumor markers in diagnosis of patients with ovarian cancer.
Bian J; Li B; Kou XJ; Liu TZ; Ming L
Asian Pac J Cancer Prev; 2013; 14(11):6241-3. PubMed ID: 24377511
[TBL] [Abstract][Full Text] [Related]
37. Combined detection of tumor markers and serum inflammatory factors in the diagnosis and treatment of gynecologic oncology.
Wang HP; Wu HY; Wang Y; Wang L
J Biol Regul Homeost Agents; 2017; 31(3):691-695. PubMed ID: 28956419
[TBL] [Abstract][Full Text] [Related]
38. [Rational application of tumor marker CA 125 in gynecological oncology].
Durdević S; Stojanović S; Marijana BN; Maksimović M
Med Pregl; 2010; 63(3-4):195-9. PubMed ID: 21053460
[TBL] [Abstract][Full Text] [Related]
39. CA 125 in gynecological pathology--a review.
Kenemans P; Yedema CA; Bon GG; von Mensdorff-Pouilly S
Eur J Obstet Gynecol Reprod Biol; 1993 Apr; 49(1-2):115-24. PubMed ID: 8365505
[TBL] [Abstract][Full Text] [Related]
40. Plasma D-dimer measurement as a marker of gynecologic tumors: comparison with Ca 125.
Rella C; Coviello M; De Frenza N; Falco G; Chiuri E; Colavito P; Quaranata M; De Leonardis A
Tumori; 1993 Oct; 79(5):347-51. PubMed ID: 8116080
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
